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The clinical and cost effectiveness of functional electrical stimulation and 1 
ankle-foot orthoses for foot drop in Multiple Sclerosis: a multicentre 2 
randomised trial 3 
Introduction 4 
Impairment of walking ability is a significant concern for 85% of people with Multiple 5 
Sclerosis.1 Foot drop, a frequently occurring problem in Multiple Sclerosis presents 6 
as a reduction in dorsiflexion during heel strike and the swing phase of walking, 7 
resulting in poor foot clearance, increasing the risks of trips and falls and impacting 8 
on health-related quality of life.1   9 
Two assistive devices, ankle-foot orthoses and functional electrical stimulation are 10 
commonly used in the treatment of foot drop. Ankle-foot orthosis, a polypropylene 11 
device worn on the lower leg and foot, limits the range of motion at the ankle and 12 
aids foot clearance.2 Functional electrical stimulation, delivers electrical stimulation 13 
applied to the common peroneal nerve by means of surface or implanted electrodes, 14 
contracting the anterior tibialis muscle during the swing phase of gait.3  15 
The effects of both devices on walking can be described as orthotic (the difference 16 
walking with the device compared to without), or therapeutic (the difference walking 17 
without the device over time). There is growing evidence of positive initial and 18 
ongoing orthotic effects of functional electrical stimulation.4 Despite ankle-foot 19 
orthoses being considered as usual care in the United Kingdom, few studies have 20 
investigated their impact on gait in Multiple Sclerosis 5,6 and only three small studies 21 
have compared the effects of both devices.7-9 The cost benefit of functional electrical 22 
stimulation has been investigated in Multiple Sclerosis 10,11, however no comparison 23 
between these devices has been undertaken.    24 
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The primary aim of our study was to compare the clinical and cost effectiveness of 25 
ankle-foot orthoses and functional electrical stimulation over 12 months in people 26 
with Multiple Sclerosis presenting with foot drop.  27 
Methods 28 
This study was prospectively registered with the UK Clinical Trials Gateway 29 
(Identifier: 15884) https://www.ukctg.nihr.ac.uk/clinical-trials/search-for-a-clinical-30 
trial/. The study was funded by the Multiple Sclerosis Society UK (grant reference: 31 
001). It commenced on 1st April 2014 and was completed on 31st March 2018. 32 
Ethical approval was granted by the West of Scotland Research Ethics Committee 33 
(14/WS/0014) and the study was sponsored by NHS Ayrshire and Arran Research 34 
and Development department. A fully powered, multicentre, non-blinded, randomised 35 
trial design was employed.  36 
 37 
Potential participants known to Multiple Sclerosis healthcare practitioners working 38 
across seven out-patient centres in Scotland; Ayrshire & Arran, Greater Glasgow & 39 
Clyde, Dumfries and Galloway, Lanarkshire, Lothian, Fife and Tayside, were 40 
informed of the study and issued with a participant information sheet. Potential 41 
participants contacted the researchers if they were interested in participating. 42 
Participants required to have; a clinical diagnosis of Multiple Sclerosis, persistent 43 
foot drop (lasting a minimum of 3 months) observed during a 5-minute walk test, 44 
stable disease (no change in the Extended Disability Status Score12 or relapse in 45 
previous 3 months), 5° of passive dorsiflexion, and tolerance of functional electrical 46 
stimulation. Participants were excluded if they had; previously used functional 47 
electrical stimulation or an ankle-foot orthosis for foot drop, moderate to severe 48 
cognitive impairment (scored < 26, Montreal Cognitive Assessment13), foot drop due 49 
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to other disorders, other conditions significantly affecting gait, contraindications to 50 
functional electrical stimulation, marked proximal weakness, plantar flexor spasticity, 51 
stance phase instability or severe lower limb/ trunk ataxia affecting gait.  52 
 53 
Potential participants were screened for eligibility, and written informed consent was 54 
gained prior to randomisation. Participants were randomly assigned (1:1) to receive 55 
an ankle-foot orthosis or functional electrical stimulation device, by selecting the next 56 
envelope from eighty-five randomly ordered prefilled sealed opaque envelopes. 57 
Demographics were collected; age, gender, Multiple Sclerosis subtype and time 58 
since diagnosis. Disability was determined by the Extended Disability Status Score 59 
by an unblinded assessor trained in the Neurostatus Scoring System.14  60 
 61 
Outcome measures were administered by two unblinded assessors (RH and AL) at 62 
baseline (0), 3, 6 and 12 months, except for the Psychological Impact of Assistive 63 
Devices Score15 which was administered at twelve months only. The primary 64 
outcome was walking speed as measured by the 5-minute self-selected walk test. 65 
Participants walked twice, once with their device and once without, resting for 20 66 
minutes between. The order of testing was randomised between participants but was 67 
kept consistent for each participant throughout the trial. Participants walked at their 68 
preferred walking speed around a 9.5m elliptical course for 5 minutes, resulting in a 69 
10-meter shuttle length. The total distance walked was recorded and the mean 70 
walking speed (m/s) calculated. This protocol has been used previously by our 71 
group.16-18   72 
 73 
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Two further secondary walking outcomes; the oxygen cost of walking and Timed 25 74 
Foot Walk19 were included. The oxygen cost of walking was measured during the 5-75 
minute self-selected walk test. Participants wore the COSMED K4b2 (COSMED, 76 
Rome, Italy) portable gas analysis system, a facemask (Hans Rudolph Inc., Kansas 77 
City, MO, USA) and Polar heart-rate monitor (Polar, Finland). Calibration was 78 
undertaken prior to each assessment and participants sat for 5 minutes prior to the 79 
test to ensure resting metabolism was established. The oxygen uptake per kilogram 80 
body weight (mL min-1kg-1) recorded between minutes three and four of the walk test 81 
was used to determine the oxygen cost per unit distance walked (mL min-1kg-1m-1), 82 
The COSMED system is a valid system for measuring oxygen uptake in healthy 83 
adults.20 For the Timed 25 Foot Walk participants walked along a 25 foot course “as 84 
quickly as possible, but safely”. The test was repeated four times, twice with and 85 
twice without the device. The time taken to complete the walks was recorded using a 86 
stop watch and the mean time for each pair of walks was used to calculate gait 87 
speed (m/s).  88 
 89 
Other secondary patient reported outcome measures included; the Multiple Sclerosis 90 
Impact Scale-2921, Multiple Sclerosis Walking scale-1222, Modified Fatigue Impact 91 
Scale23, Activities-specific Balance and Confidence Scale24, Euroquol five-dimension 92 
five-level questionnaire (EQ-5D-5L)24 and Psychological Impact of Assistive Devices 93 
Scale.15 The Multiple Sclerosis Impact scale-29 has two sub scales; physical and 94 
psychological, with higher scores indicating a greater physical and psychological 95 
impact of Multiple Sclerosis on an individual’s life. The Psychological Impact of 96 
Assistive Devices scale consists of three subscales; Competence (C), Adaptability 97 
(A), and Self-Esteem (SE) which measure the impact of assistive devices on 98 
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functional independence, well-being, and quality of life.26 The EQ-5D-5L consists of a 99 
visual analogue scale of perceived health from zero to one hundred and a 100 
questionnaire, the results from which were converted to a utility index, which was 101 
used to calculate a health outcome measure, quality-adjusted life years.  102 
 103 
Participants randomised to the usual care group were fitted with a custom-made, 104 
solid, ankle-foot orthosis by an orthotist, within four weeks of their initial assessment. 105 
The recommendations made by the Best Practice Statement for ankle-foot orthoses 106 
following stroke were applied.27 The orthoses were made with 5mm homopolymer 107 
polypropylene, trim lines were anterior to the malleoli and reinforcements added to 108 
the ankle section as required. The angle of the tibia was inclined forward, 109 
approximately 10 to vertical and each orthosis was ‘tuned’ by the addition or 110 
removal of small heel wedges.   111 
 112 
Participants randomised to the functional electrical stimulation group were assessed 113 
and fitted with an Odstock Dropped Foot Stimulator Pace (OML, Salisbury) device by 114 
a physiotherapist experienced in functional electrical stimulation (AL). Wired heel 115 
switches and a stimulation frequency of 40Hz were applied. Electrode position, pulse 116 
width, waveform and ramping parameters were adjusted for each participant in order 117 
to achieve a comfortable and efficient muscle contraction. The current amplitude 118 
ranged from 7 to 72mA (mean=40mA). Participants in both groups were instructed to 119 
gradually increase the wear of their devices over the first few 6 weeks.       120 
 121 
Data analysis 122 
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Data from the 5-minute self-selected walk test collected from our initial study5 was 123 
applied to determine the sample size. A minimum of thirty-seven participants were 124 
required to detect a change of at least 75% of 1 standard deviation value (0.16 m/s) 125 
to achieve a power of 90% at a 5% level of significance. Eighty-five participants were 126 
recruited allowing for an approximate 15% attrition rate.  127 
 128 
Descriptive statistics for demographic data are presented as means and standard 129 
deviations unless otherwise indicated. A repeated measures ANOVA model was 130 
employed to analyse the outcome variables where the main factors, Group (ankle-131 
foot orthoses/functional electrical stimulation), Time (Baseline (0), 3, 6, 12 months) 132 
and for the speed and oxygen cost of walking measures, the Condition (with/without 133 
device) and their interactions. The estimated means, standard errors and estimated 134 
differences were calculated to inform the ongoing and total orthotic effects and the 135 
therapeutic effect on the objective walking outcomes. A Restricted Maximum 136 
Likelihood approach to fitting mixed models was employed to allow intention to treat 137 
assumptions to cope with missing data. All analysis was performed on IBM SPSS 138 
v24, using a 5% level of significance. 139 
 140 
A cost-utility analysis was performed to compare the value for money of functional 141 
electrical stimulation with ankle-foot orthoses (usual care). A National Health Service 142 
and Personal Social Services perspective analyses was adopted and a discount rate 143 
of 3.5% to future costs and health benefits was applied as recommended by the 144 
National Institute for Clinical Excellence.28 Equipment costs for both devices were 145 
derived from purchase costs at the time of the study. National Health Service staff 146 
costs were based on time spent delivering the interventions during the clinical trial, 147 
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following interviews with the clinicians involved. The staff time was then multiplied by 148 
the relevant Information Services Division unit cost. The EQ-5D-5L data was 149 
converted to a utility index using a published algorithm29 and analysis applied the 150 
area under the curve method to determine quality-adjusted life years. Missing values 151 
were accounted for by carrying forward the last data point and drop outs were 152 
assumed to revert to an average of the baseline values to capture expected disease 153 
progression. The analysis adopted a time horizon of two years to determine cost-154 
effectiveness for a further year beyond the trial. The analysis assumes that quality-155 
adjusted life years estimates derived over the first year are maintained for the 156 
additional 12 months. Uncertainty was evaluated by undertaking a sensitivity 157 
analysis, by varying a number of parameters by up to 10%. Several scenarios were 158 
analysed to test the sensitivity of the model to changes in structural assumptions. 159 
The base case results are presented as an incremental cost-effectiveness ratio. An 160 
incremental cost-effectiveness ratio below the standard threshold of £20,000 161 
(€22962.00) -£30,000(€34443) per quality-adjusted life year is indicative that an 162 
intervention is cost-effective.30 The incremental cost-effectiveness ratio for functional 163 
electrical stimulation was calculated using the following standard formula: 164 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐹𝐸𝑆 − 𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝐹𝑂
𝑇𝑜𝑡𝑎𝑙 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐹𝐸𝑆 − 𝑇𝑜𝑡𝑎𝑙 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝐹𝑂
 
Abbreviations- FES: functional electrical stimulation; AFO: ankle-foot orthoses; 165 
QALYs: quality-adjusted life years  166 
Results 167 
Eighty-five participants met the criteria for inclusion and consented to participate in 168 
the study between September 2014 and January 2017 (Figure 1). Five participants 169 
withdrew between the screening and assessment visit. Seventy-nine participants 170 
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completed the baseline assessment and were included in subsequent analysis. The 171 
recruitment and flow of patients through the study is shown in Figure 1, and the 172 
baseline demographic data are detailed in Table 1. Thirty-seven participants dropped 173 
out over the course of the study and although there was no statistically significant 174 
difference in drop-out rates between the groups, the proportion was higher in the 175 
ankle-foot orthoses group. 176 
 177 
Insert Figure 1 near here 178 
 179 
Insert Table 1 near here 180 
 181 
Table 2 presents the data for all outcomes, for both groups, at all assessment points 182 
(0, 3, 6, 12 months) and the results for the repeated measures ANOVA model 183 
employed for all outcomes.   184 
 185 
Impact of devices on measures of walking performance 186 
For the primary outcome measure, walking speed as measured by the 5-minute self-187 
selected walk test, a significant difference was observed between the groups 188 
(p=0.005) with the functional electrical stimulation group consistently walking faster 189 
at all assessment points. Over the 12 months a significant improvement occurred in 190 
both groups (p<0.001), although the groups changed differently over this time 191 
(p=0.028). The functional electrical stimulation group improved steadily for the first 6 192 
months then declined, whereas changes in the ankle-foot orthoses group fluctuated 193 
over 12 months. There was no significant difference between the groups with 194 
regards to the effects of the devices.   195 
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 196 
For the Timed 25 Foot Walk the functional electrical stimulation group walked faster 197 
overall compared to the ankle-foot orthoses group (p=0.043). There was no 198 
significant difference between the groups, nor did the groups react differently over 199 
the 12 months. There was a significant change in oxygen cost of walking at 12 200 
months (p=0.002) for both groups, however there was no difference between the 201 
groups.  202 
 203 
Insert Table 2 here 204 
 205 
Impact of devices on Patient Reported Outcome Measures 206 
Significant improvements in the physical sub-scale of the Multiple Sclerosis Impact 207 
Scale (p=0.040) and the Multiple Sclerosis Walking scale-12 (p=0.002) were 208 
observed and this was most notable at 3 months in both groups respectively 209 
(p=0.045; p<0.001). There were no differences between the groups for Patient 210 
Reported Outcome Measures, except for all sub scales of the Psychological Impact 211 
of Assistive Devices Scale, where the functional electrical stimulation group 212 
demonstrated significantly higher scores for Competence (p=0.016), Adaptability 213 
(p=0.001) and Self-Esteem (p =0.006) at 12 months.  214 
 215 
Orthotic and therapeutic effects on the speed and oxygen cost of walking 216 
Clinically significant effects were determined by an observed increase in walking 217 
speed of ≥ 0.05m/s, which has been previously identified by Perera et al.31 A 218 
clinically significant ongoing orthotic effect for both walk tests was demonstrated in 219 
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the functional electrical stimulation, but not the ankle-foot orthoses group (Table 3). 220 
A clinically significant total orthotic effect on the primary walking outcome measure 221 
was noted in the ankle-foot orthoses, but not the functional electrical stimulation 222 
group at 12 months.  223 
There was a negative total orthotic and therapeutic effect on oxygen cost of walking 224 
with both devices, except for the ankle-foot orthoses at 12 months where a positive 225 
total orthotic effect was observed.  226 
  227 
Insert Table 3 here 228 
 229 
Cost effectiveness 230 
The total quality-adjusted life years were higher for functional electrical stimulation 231 
than ankle-foot orthoses (Table 4). Further deterministic sensitivity and scenario 232 
analysis indicated that the base case incremental cost-effectiveness ratio in the two-233 
year model was relatively robust to changes in parameter values or structural 234 
assumptions.  235 
 236 
Insert Table 4 here 237 
 238 
Discussion 239 
Both devices demonstrated improvements in walking speed at 12 months, although 240 
there were no significant differences in their effects. There were many drop outs over 241 
the course of the study and the proportion was higher for ankle-foot orthoses, 242 
although there was no statistically significant difference between the groups.  The 243 
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non-significant positive ongoing orthotic effects observed with functional electrical 244 
stimulation were of a similar magnitude to the results previously published in a meta-245 
analysis from our group with respect to the combined long walk (i.e. 0.04m/s), but 246 
not the short walking tests (i.e. 0.08m/s).4 Two small studies previously investigating 247 
the ongoing orthotic effect of ankle-foot orthoses on walking speed reported 248 
inconclusive results.5,6 Only three small non randomised studies have previously 249 
compared the impact of these two devices on walking outcomes in Multiple 250 
Sclerosis.7-9 Sheffler et al.7 reported mixed results on gait speed (n=4), and a more 251 
recent study (n=20)9 found no difference between the devices on the speed or 252 
energy cost of walking. Street et al.8 reported a significant difference in walking 253 
speed (n=40, p=0.03) in favour of functional electrical stimulation, however 254 
participants issued with functional electrical stimulation had already rejected ankle-255 
foot orthoses, potentially biasing results. Such results suggest that devices may offer 256 
similar efficacy, or that the walking performance measures selected may not be 257 
sensitive enough to detect differences that exist.  258 
 259 
No clinically significant therapeutic effects on walking speed were observed in either 260 
group, although the pattern of effect was different. Results from a recent meta-261 
analysis comparing the therapeutic effect of both devices in a stroke and cerebral 262 
palsy population also reported comparable positive effects.32 No previous studies 263 
have evaluated therapeutic effects of ankle-foot orthoses in Multiple Sclerosis, 264 
however several functional electrical stimulation studies have investigated these 265 
effects over shorter time frames33-37 with inconclusive results. Our previous meta-266 
analysis reported a deterioration in unstimulated walking speed during long walking 267 
tests following 20 weeks of functional electrical stimualtion.4 Nevertheless, Street et 268 
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al.35 reported a third of participants gained clinically meaningful therapeutic effects, 269 
whilst a third experienced a decline in walking over the same time frame. Given the 270 
neurodegenerative nature of Multiple Sclerosis it seems unlikely that either device 271 
could offer a therapeutic effect over the longer time frame investigated in our study. 272 
However, as observed by Street et al.35 it may be possible that a sub group of people 273 
with Multiple Sclerosis have the potential to experience such effects and we 274 
observed small positive therapeutic effects with ankle-foot orthoses at 12 but not 6 275 
months. This finding suggests that changes may take longer than 6 months to 276 
develop with ankle-foot orthoses. Further kinematic and neural control studies are 277 
required to corroborate these findings and to understand the possible underlying 278 
therapeutic mechanisms of these devices in people with Multiple Sclerosis.              279 
 280 
There were no significant differences between the devices with regards to their 281 
impact on the oxygen cost of walking. To our knowledge only one other study has 282 
compared the ongoing orthotic effects of these devices on the energy and efficiency 283 
of gait and reported no difference between these devices.9 Nevertheless, there were 284 
different patterns of effects observed between the groups, with the functional 285 
electrical stimulation group demonstrating small non-significant positive orthotic 286 
effects throughout, and the ankle-foot orthoses group observing a greater positive 287 
total orthotic effect (-0.05 mL min-1 kg-1m-1; 14.7%). These results are difficult to 288 
interpret. However, they may have been influenced by the lower baseline oxygen 289 
cost of walking in the functional electrical stimulation group.  290 
 291 
There was no difference between the groups with regards to the patient reported 292 
outcomes, except for the Psychological Impact of Assistive Devices Score where 293 
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participants in the functional electrical stimulation group reported significantly higher 294 
scores for all three subscales. Two previous studies evaluated the impact of 295 
surface34 and implantable40 functional electrical stimulation on the Psychological 296 
Impact of Assistive Devices Score. Scores for the functional electrical stimulation 297 
group in the current study (Competence (1.53); Acceptance (1.00); Self Efficacy 298 
(1.41)) were similar to those observed by Taylor et al.40 (Competence (1.59); 299 
Acceptance (1.34); Self Efficacy (1.44)). The Psychological Impact of Assistive 300 
Devices Scale has been found to be predictive of device compliance and retention 301 
and is responsive to device stigma.41 Higher scores observed in the functional 302 
electrical stimulation group suggests that device acceptance may be greater than 303 
ankle-foot orthoses. Although both devices aim to promote functional autonomy, 304 
assistive technology can be viewed as a symbol of disability, a loss of independence 305 
and altered self-image.42 Some participants in the ankle-foot orthoses group reported 306 
that wearing their device emphasised their disability and this may have contributed to 307 
the higher rate of device abandonment observed in this group. Squires et al.43 308 
suggests that assistive technology needs to meet both the physical and 309 
psychological needs of an individual to ensure positive outcomes and continued use. 310 
Future studies therefore need to consider the psychological acceptance of a device 311 
in addition to its impact on walking outcomes.  312 
 313 
Against a background of financial constraints there is a need for evidence of the cost 314 
benefits of interventions. Our study indicates that although the upfront costs of 315 
functional electrical stimulation are greater than usual care (ankle-foot orthoses), it 316 
may be considered as a potentially cost-effective treatment option for foot drop and 317 
offers a value for money alternative in Multiple Sclerosis. The incremental cost 318 
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effectiveness ratio for year one and two for functional electrical stimulation were 319 
below the National Institute for Health and Care Excellence’s conventional 320 
thresholds of £20,000 (€22962)-£30,000 (€34443) per quality-adjusted life year.28 No 321 
previous studies have examined cost effectiveness of functional electrical stimulation 322 
exclusively within Multiple Sclerosis or compared the cost effectiveness of these two 323 
devices. Two previous economic evaluations which examined the cost effectiveness 324 
of functional electrical stimulation in a mixed neurological population reported 325 
incremental cost-effectiveness ratios of £25,235 (€28972.30) over one year, 326 
reducing to £12,431 (€14272) over five years10 and £15,406 (€17688) compared to 327 
physiotherapy.11 An economic report undertaken in 2009 found that functional 328 
electrical stimulation was likely to be cost-effective, although data were almost 329 
exclusively from studies recruiting stroke participants.44 The results of our current 330 
economic analysis concur with these previous investigations and suggests that 331 
further improvements in cost-effectiveness of the device could be gained with greater 332 
compliance, thus offsetting the upfront costs and allowing the benefit of treatment to 333 
accrue over the longer term.  334 
 335 
This study has several limitations. Despite this study being powered to detect 336 
change, the relatively small number of participants recruited and the high overall 337 
dropout rates, with a greater loss from the ankle-foot orthoses group, make it difficult 338 
to draw definitive conclusions. In addition, the participant, assessor and treatment 339 
provider were not blinded, thus ascertainment bias is likely, although such bias may 340 
be less relevant with objective outcomes, such as gait speed.45  341 
 342 
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The multi-centre design of this study enhances the generalisability of results. 343 
However, although the ankle-foot orthoses prescription was standardised, variations 344 
did occur across sites. Ankle-foot orthoses specification can influence biomechanical 345 
aspects of gait, thus impacting on walking performance outcomes46 and device 346 
retention. The ankle-foot orthoses prescription employed was based on stroke 347 
guidelines and it is not clear whether this prescription was the most appropriate for 348 
people with Multiple Sclerosis, particularly those presenting with a less severe foot 349 
drop where such a rigid design may have resulted in higher drop outs. Further 350 
investigation is required to identify the most appropriate and acceptable prescription. 351 
We excluded participants with stance phase instability and reduced passive range of 352 
ankle motion, therefore, findings are only applicable to those with mainly swing 353 
phase impairments.  354 
 355 
Although the 6-minute Walk Test has been found to be an accurate walking 356 
performance test to assess the benefits of assistive technology for foot drop in 357 
Multiple Sclerosis47, the validity and reliability of our primary outcome, the 5-minute 358 
self-selected walk test, has not been established. This is a significant limitation of 359 
this study. 360 
 361 
The inclusion of an economic analysis is a strength. However, analysis did not 362 
consider the impact on other healthcare resources, the time horizons were short, and 363 
the differences detected in quality-adjusted life years for both devices were small. 364 
Therefore, despite undertaking sensitivity and scenario analyses, the results should 365 
be treated with caution. 366 
 367 
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Results from this randomised trial which to the best of our knowledge is the first and 368 
largest study undertaken comparing the clinical and cost effectiveness of two 369 
interventions for foot drop in Multiple Sclerosis over 12 months has provided 370 
evidence that functional electrical stimulation is a comparable to ankle-foot orthoses 371 
with regards to its impact on walking speed and patient reported outcomes. Although 372 
this study suggests that functional electrical stimulation may also provide a value for 373 
money alternative to usual care, a larger study which includes follow up of device 374 
drop outs, and the employment of long-term modelling to explore the cost and 375 
quality-adjusted life years of both interventions over the lifetime of a person with 376 
Multiple Sclerosis, is required before definitive conclusions can be drawn with 377 
regards to the cost effectiveness of functional electrical stimulation. Further 378 
investigation as to how both interventions impact on walking, from a biomechanical, 379 
muscle activation, neural control and personal perspective is also recommended. 380 
The results from this study will nevertheless begin to inform clinical decisions and 381 
contribute towards future policy decisions regarding the management of foot drop, 382 
ultimately improving outcomes for people with Multiple Sclerosis.  383 
 384 
Clinical messages 385 
 Ankle-foot orthoses and functional electrical stimulation have comparable 386 
positive orthotic effects on gait speed in Multiple Sclerosis.  387 
 Despite higher initial upfront costs for functional electrical stimulation, it offers 388 
a value for money alternative to usual care.   389 
 More people stopped using ankle-foot orthoses than functional electrical 390 
stimulation over twelve months.   391 
 392 
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Table 1.  Demographic characteristics of participants.  564 
 AFO FES p 
n 38 41  
Mean age [years] 51.4[11.2] 
 
50.4 [10.4] 0.684a 
Gender % Male 52.6%  20.0%   0.006c * 
Type of MS            
                    Primary Progressive  
Secondary Progressive 
Relapsing Remitting 
Unknown 
 
21.1% 
26.3% 
42.1% 
10.5% 
 
15.0% 
20.0% 
45.0% 
20% 
 
 
0.6647c 
Mean time since  
diagnosis [years]  
 
10.2[10.3] 
 
 
7.6[8.6] 
 
0.205b 
Mean Extended Disability 
Status Scale 
5.3[1.3] 4.9[1.4] 0.136b 
Abbreviations- n: number; AFO: ankle-foot orthoses; FES: functional electrical stimulation; 565 
MS: Multiple Sclerosis. 566 
Data values are mean [SD] for continuous variables and n (%) for categorical variables 567 
unless otherwise stated. Between group differences for demographic data (a: t-test, b: Man-568 
Whitney, c: chi-square, *: significant).  569 
  570 
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Table 2: Means and SD for the primary and secondary outcome measures in the intervention and usual care group at 0,3,6 and 12 months.  571 
 Baseline 
(0) 
 3 mo  6 mo  12 mo  ANOVA 
Results 
   
 AFO FES AFO FES AFO FES AFO FES Group Time Group/Time 
interaction 
Group/with 
v without 
device 
5minSSWT (without) m/s 0.62[0.21] 0.73[0.27] 0.69[0.23]
a 
0.75[0.26]
a 
0.65[0.25]
b, c 
0.78[0.27]
b,c 
0.71[0.25]
d 
0.73[0.26]
d 
P=0.005* P<0.001* P=0.028* P=0.714 
5minSSWT (with) m/s 0.61[0.22] 0.74[0.25] 0.72[0.22]
a 
0.81[0.26]
a 
0.68[0.27]
b,c 
0.83[0.27]
b,c 
0.73[0.24]
d 
0.79[0.24]
d 
    
25ftWT (without) m/s 0.86[0.34] 0.94[0.34] 0.89[0.30] 0.95[0.30] 0.98[0.29] 0.93[0.29] 0.96[0.31] 0.95[0.30] P=0.043* P=0.279 P=0.310 P=0.571 
25ftWT (with) m/s 0.83[0.30] 0.97[0.33] 0.90[0.27] 1.00[0.29] 0.88[0.29] 0.99[0.29] 0.98[0.29] 1.00[0.29]   .  
O2 cost (without) mLmin
-1
kg
-1 
m
-1 
0.34[0.16] 0.29[0.14] 0.22[0.18] 0.31[0.21] 0.36[0.17]
e 
0.31[0.26]
w 
0.35[0.21]
f,g 
0.33[0.20]
f,g
 P=0.177 P=0.002* P=0.093 P=0.989 
O2 cost (with) mLmin
-1
kg
-1
m
-1
 0.35[0.16] 0.28[0.12] 0.31[0.14] 0.28[0.11] 0.38[0.18]
e 
0.28[0.23]
e 
0.35[0.32]
f,g 
0.29[0.15]
f,g 
    
MSIS-29 (physical) 37.0[13.3] 35.7[18.1] 33.8[14.3]
h 
33.9[16.1]
h 
31.6[13.0] 34.0[17.7]
 
33.8[15.2] 34.2[17.4] P=0.836 P=0.040* P=0.819  
MSIS-29 (psych) 14.0[8.9] 13.0[8.3] 13.8[8.1] 12.6[7.9] 11.6[6.8] 13.0[8.1] 12.5[7.2] 12.2[7.2] P=0.056 P=0.987 P=0.873  
MSWS-12 33.8[8.3] 30.4[12.1] 29.5[10.3]
i 
27.2[12.0]
i 
31.2[9.4]
j 
27.9[11.0]
j 
28.9[11.9]
 
29.9[12.4] P=0.202 P=0.002* P=0.243  
EQ-5D-VAS 67.7[16.5] 70.2[19.3] 67.7[18.7] 72.5[17.5] 66.0[19.0] 71.5[21.4] 68.8[18.9] 74.3[15.5] P=0.169 P=0.257 P=0.795  
MFIS 11.5[4.1] 11.7[5.3] 11.3[4.0] 11.1[4.9] 11.0[4.2] 11.2[4.9] 11.3[4.8] 11.9[4.5] P=0.888 P=0.233 P=0.433  
ABC 50.2[18.9] 54.4[23.6] 51.2[19.4] 56.7[21.4] 52.6[20.5] 56.4[20.9] 52.2[23.5] 53.7[20.3] P=0.378 P=0.934 P=0.741  
PIADS C       0.85[1.01] 1.53[1.05] P=0.0016*    
PIADS A       0.38[0.97] 1.41[0.98] P=0.001*    
PIADS SE       0.45[0.67] 1.00[0.68] P=0.006*    
Abbreviations- mo: months; AFO: ankle foot orthoses; FES: functional electrical stimulation; 5minSSWT: 5 minute self-selected walk test: m/s; 572 
meters per second: 25ftWT: 25 foot walk test; O2 cost (mLmin-1kg-1m-1); oxygen cost of walking per unit distance walked: MSIS-29 (physical); 573 
Multiple Sclerosis Impact Scale-29 physical sub scale: MSIS-29 (psych); Multiple Sclerosis Impact Scale-29 psychological sub scale: MSWS-574 
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12; Multiple Sclerosis walking scale-12: EQ-VAS; Euroqual questionnaire visual analogue scale; MFIS; modified fatigue impact scale; ABC: 575 
activities and balance confidence scale; PIADS C: psychological impact of assistive devices scale competence sub scale; PIADS A: 576 
adaptability subscale; PIADS SE: self-esteem subscale; *: statistically significant difference detected; a: ANOVA sig time effect 0-3months, 577 
p<0.001; b: ANOVA sig time effect 0-6 months, p=0.029; c: ANOVA sig time effect 3-6 months, p=0.028; d: ANOVA sig time effect 3-12 months, 578 
p=0.09; e: ANOVA sig time effect 3-6 months, p=0.07; f:  ANOVA sig time effect 0-12 months, p=0.011; g: ANOVA sig time effect 3-12 months, 579 
p=0.001; h: ANOVA sig time effect 0-3 months, p=0.045; I: ANOVA sig time effect 0-3 months, p<0.001; j : ANOVA sig time effect 3-6 months, 580 
p=0.035.     581 
27 
 
Table 3: Estimated means (SE) of initial, ongoing and total orthotic and therapeutic effects of 582 
AFO and FES on the 5minSSWT, 25ftWT and the oxygen cost of walking.  583 
   AFO   FES  
 without with  without with  
IO        
5minSSWT(m/s) 0.63(0.04) 0.61(0.04) -0.02 0.73(0.04) 0.74(0.04) +0.01 
25ftWT(m/s) 0.86(0.06)  0.83(0.05) -0.03 0.85(0.05) 0.87(0.05) +0.03 
O2 cost (mLmin
-1
kg
-1
 m
-1
) 0.34(0.03) 0.35(0.03) +0.01 0.29(0.02) 0.28(0.02) -0.01 
OO (3mo)       
5minSSWT(m/s) 0.67(0.04) 0.70(0.04) +0.03 0.76(0.05) 0.81(0.05) +0.05
a 
25ftWT(m/s) 0.86(0.05) 0.87(0.05) +0.01 0.95(0.05) 0.99(0.05) +0.04 
O2 cost (mLmin
-1
kg
-1
 m
-1
) 0.33(0.03) 0.31(0.03) -0.02 0.32(0.03) 0.29(.03) -0.03 
OO (6mo)       
5minSSWT(m/s)  0.61(0.04) 0.65(0.04) +0.04 0.76(0.04) 0.81(0.04) +0.05
a 
25ftWT(m/s) 0.84(0.05) 0.82(0.05) -0.02 0.92(0.05) 0.97(0.05) +0.05
a 
O2 cost (mLmin
-1
kg
-1
 m
-1
) 0.35(0.03) 0.38(0.03) +0.03 0.33(0.04) 0.32(0.04) -0.01 
OO (12mo)       
5minSSWT(m/s) 0.66(0.04) 0.67(0.04) +0.02 0.71(0.05) 0.76(0.05) +0.05
a 
25ftWT(m/s)  0.88(0.06) 0.90(0.06) +0.02 0.91(0.05) 0.96(0.05) +0.05
a 
O2 cost (mLmin
-1
kg
-1
 m
-1
) 0.38(0.05) 0.39(0.05) +0.01 0.39(0.05) 0.36(0.05) -0.03 
TO (12mo)       
5minSSWT(m/s)   +0.05
a 
  +0.03 
25ftWT(m/s)   +0.04   +0.02 
O2 cost (mLmin-1kg
-1
 m
-
1
) 
  -0.05   +0.07 
Th (6mo)       
5minSSWT(m/s)   -0.02   +0.03 
25ftWT(m/s)   -0.02   -0.02 
O2 cost (mLmin-1kg
-1
 m
-
1
) 
  +0.01   +0.04 
Th (12mo)       
5minSSWT(m/s)   +0.03   -0.02 
25ftWT(m/s)   +0.02   -0.03 
O2 cost   +0.04   +0.10 
Abbreviations- AFO; ankle foot orthoses; FES: functional electrical stimulation;  = effect of 584 
estimated means; IO: initial orthotic effect; OO: ongoing orthotic effect; TO (12mth): total 585 
orthotic effect at 12 months; Th (12mth): therapeutic effect at 12 months; mo: months; 586 
5minSSWT: 5-minute self-selected walk test: m/s: meters per second; 25ftWT: Timed 25 foot 587 
walk; O2 cost (mL min
-1 kg-1 m-1); oxygen cost of walking per unit distance walked; a indicates 588 
a mean change in walking speed of ≥ 0.05m/s, considered to be clinically significant.     589 
 590 
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Table 4: Treatment costs, quality-adjusted life years and incremental cost effectiveness 591 
ratio’s for both devices over both one and two years. (year two costs represent the 592 
cumulative total of year one and year two costs). 593 
Year 1      
Treatment 
Total cost per year 
including 
equipment and 
staff costs (£/€) 
Total 
QALYs Inc. cost (£/€) 
Inc. 
QALY ICER (£/€) 
AFO 579.76/665.62 0.65 
   FES 1,228.02/1409.89 0.68 648.26/744.27 0.03 25,588.96/29378.68 
Year 2      
Treatment 
Total cost per year 
including 
equipment and 
staff costs (£/€) 
Total 
QALYs Inc. cost (£/€) 
Inc. 
QALY ICER (£/€) 
AFO 723.00/830.08 1.31 
   FES 1,446.83/1661.11 1.36 723.83/831.03 0.05 14,285.92/16401.66 
 594 
Abbreviations- AFO; ankle foot orthoses; FES: functional electrical stimulation; inc: 595 
incremental; QALY: quality adjusted life year; ICER: incremental cost effectiveness ratio. 596 
Values presented are British pounds and euros.  597 
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 612 
Figure 1: Consort diagram.  613 
Abbreviations: AFO: ankle-foot orthoses, FES: functional electrical stimulation   614 
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 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
Assessed for eligibility (n=96) 
Excluded (n=11) 
   Didn’t meet inclusion criteria (n=9) 
   Didn’t want to be randomised (n=1) 
   Unable to commit (n=1) 
Completed Week 12 assessment (n=32) 
 Discontinued intervention due to AFO 
being uncomfortable, too bulky or difficult 
to accommodate footwear (n=6) 
 
 
Allocated to AFO intervention (n=43) 
 Received allocated intervention (n=38) 
 Did not receive allocated intervention (n=5) 
 Not happy with group allocation (n=3) 
 Not happy with AFO (n=2) 
  
Completed Wk 12 assessment (n=37) 
 Discontinued intervention (n=4) 
due to relapse (n=1), unable to 
commit to study (n=2), disease 
progression (n=1) 
 Missed assessment (n=3)  
Allocated to FES intervention (n= 42) 
 Received allocated intervention (n=41 ) 
 Did not receive allocated intervention 
(n=1) 
 Unable to commit to study 
 
Allocation  
Week 24 
Week 12  
Randomized (n=85) 
Enrolment 
Completed Week 24 assessment (n=26) 
 Discontinued intervention (n=3) due to 
unable to commit to study (n=1), not 
happy with AFO (n=1), lost contact (n=1) 
 Missed assessment (n=3) 
 Missed appointments (n=5) 
 
Completed Week 24 assessment 
(n=37) 
 
 
Completed Week 52 assessment (n=31) 
 Discontinued intervention (n=6); lost 
contact (n=2), relapse (n=1), not 
finding FES helpful (n=2), increased 
neuropathic pain preventing 
use(n=1) 
 Missed assessment (n=1) 
Completed Week 52 assessment (n=22) 
 Discontinued intervention (n=7); not 
happy with/not using AFO (n=3), 
disease progression (n=3), unwell 
(n=1), lost contact (n=1) 
 
Week 52 
